Apr. 12 at 12:54 PM
$CRMD $DVA $FMS $ICUI
Davita real world rollout of Clearguard caps reduced infections 34%
“A total of 37,642 patients in the pre-period and 40,498 patients in the post-period met eligibility criteria. Overall BSI rate fell from 0.54/100 CVC days in the pre-period to 0.36/100 CVC days after AmBC ”
https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3442083
Davita trial with Clearguard HD vs alcohol caps (~800 people each arm)
“the ClearGuard group had a BSI rate significantly lower than that of the Tego+Curos group (0.28 versus 0.75 PBCs per 1000 CVC-days, respectively; P=0.001)”
https://pmc.ncbi.nlm.nih.gov/articles/PMC5875956/
Fresenius trial with Clearguard HD vs standard caps (~1200 people each arm)
“When considering sustained use (defined as last 6 months of the study), the intervention versus the control was associated with a 69% lower BSI rate (0.22 vs 0.72/1,000 CVC-days, respectively; P=0.01)”
https://pubmed.ncbi.nlm.nih.gov/27839894/
